Opyl Ltd. (AU:OPL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Opyl Limited has entered into a Service Level Agreement with Southern Clinical Development Consulting to license its TrialKey platform, enhancing clinical trial support and optimization. This collaboration aims to improve trial design, site feasibility, and patient recruitment strategies through AI-powered insights, marking a significant expansion in Opyl’s role in clinical trial management. The agreement provides Opyl with flexible revenue opportunities, as fees are determined per project based on the scope of services.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.